These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Zaki N; Chen LN; Lane R; Doherty T; Drevets WC; Morrison RL; Sanacora G; Wilkinson ST; Popova V; Fu DJ Neuropsychopharmacology; 2023 Jul; 48(8):1225-1233. PubMed ID: 37173512 [TBL] [Abstract][Full Text] [Related]
23. Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire. Kern Sliwa J; Naranjo RR; Turkoz I; Petrillo MP; Cabrera P; Trivedi M CNS Spectr; 2024 Jun; 29(3):176-186. PubMed ID: 38557430 [TBL] [Abstract][Full Text] [Related]
24. Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression. Williamson DJ; Gogate JP; Kern Sliwa JK; Manera LS; Preskorn SH; Winokur A; Starr HL; Daly EJ J Clin Psychiatry; 2022 Sep; 83(6):. PubMed ID: 36149841 [No Abstract] [Full Text] [Related]
25. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression. Martinotti G; Dell'Osso B; Di Lorenzo G; Maina G; Bertolino A; Clerici M; Barlati S; Rosso G; Di Nicola M; Marcatili M; d'Andrea G; Cavallotto C; Chiappini S; De Filippis S; Nicolò G; De Fazio P; Andriola I; Zanardi R; Nucifora D; Di Mauro S; Bassetti R; Pettorruso M; McIntyre RS; Sensi SL; di Giannantonio M; Vita A; Bipolar Disord; 2023 May; 25(3):233-244. PubMed ID: 36636839 [TBL] [Abstract][Full Text] [Related]
26. Real-world demographic and clinical profiles of patients with treatment-resistant depression initiated on esketamine nasal spray. Samalin L; Mekaoui L; De Maricourt P; Sauvaget A; Codet MA; Gaudré-Wattinne É; Wicart C; Rothärmel M Int J Psychiatry Clin Pract; 2024 Jun; 28(2):83-93. PubMed ID: 39223855 [TBL] [Abstract][Full Text] [Related]
27. Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data. Nijs M; Wajs E; Aluisio L; Turkoz I; Daly E; Janik A; Borentain S; Singh JB; DiBernardo A; Wiegand F Int J Neuropsychopharmacol; 2020 Jul; 23(7):426-433. PubMed ID: 32270176 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Fedgchin M; Trivedi M; Daly EJ; Melkote R; Lane R; Lim P; Vitagliano D; Blier P; Fava M; Liebowitz M; Ravindran A; Gaillard R; Ameele HVD; Preskorn S; Manji H; Hough D; Drevets WC; Singh JB Int J Neuropsychopharmacol; 2019 Oct; 22(10):616-630. PubMed ID: 31290965 [TBL] [Abstract][Full Text] [Related]
29. Meaningful Change in Depression Symptoms Assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) Among Patients with Treatment Resistant Depression in Two, Randomized, Double-blind, Active-controlled Trials of Esketamine Nasal Spray Combined With a New Oral Antidepressant. Hudgens S; Floden L; Blackowicz M; Jamieson C; Popova V; Fedgchin M; Drevets WC; Cooper K; Lane R; Singh J J Affect Disord; 2021 Feb; 281():767-775. PubMed ID: 33261932 [TBL] [Abstract][Full Text] [Related]
30. Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment. Dold M; Bartova L; Kasper S Int J Neuropsychopharmacol; 2020 Jul; 23(7):440-445. PubMed ID: 32570275 [TBL] [Abstract][Full Text] [Related]
31. Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study. Ochs-Ross R; Wajs E; Daly EJ; Zhang Y; Lane R; Lim P; Drevets WC; Steffens DC; Sanacora G; Jamieson C; Hough D; Manji H; Singh JB Am J Geriatr Psychiatry; 2022 May; 30(5):541-556. PubMed ID: 34750057 [TBL] [Abstract][Full Text] [Related]
32. Treatment Response With Esketamine Nasal Spray Plus an Oral Antidepressant in Patients With Treatment-Resistant Depression Without Evidence of Early Response: A Pooled Post Hoc Analysis of the TRANSFORM Studies. Turkoz I; Daly E; Singh J; Lin X; Tymofyeyev Y; Williamson D; Salvadore G; Nash AI; Macaluso M; Wilkinson ST; Nelson JC J Clin Psychiatry; 2021 Jul; 82(4):. PubMed ID: 34288609 [No Abstract] [Full Text] [Related]
33. Changing the paradigm in treatment-resistant depression: A review of long-term efficacy and tolerability of esketamine nasal spray. Herrera-Imbroda J Exp Clin Psychopharmacol; 2023 Dec; 31(6):1092-1101. PubMed ID: 37126036 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study. Castro M; Wilkinson ST; Al Jurdi RK; Petrillo MP; Zaki N; Borentain S; Fu DJ; Turkoz I; Sun L; Brown B; Cabrera P CNS Drugs; 2023 Aug; 37(8):715-723. PubMed ID: 37558912 [TBL] [Abstract][Full Text] [Related]
35. Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression. Katz EG; Hough D; Doherty T; Lane R; Singh J; Levitan B Clin Pharmacol Ther; 2021 Feb; 109(2):536-546. PubMed ID: 32860422 [TBL] [Abstract][Full Text] [Related]
36. Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant. Jamieson C; Popova V; Daly E; Cooper K; Drevets WC; Rozjabek HM; Singh J Health Qual Life Outcomes; 2023 May; 21(1):40. PubMed ID: 37158911 [TBL] [Abstract][Full Text] [Related]
37. Evaluation of Individual Items of the Patient Health Questionnaire (PHQ-9) and Montgomery-Asberg Depression Rating Scale (MADRS) in Adults with Treatment-Resistant Depression Treated with Esketamine Nasal Spray Combined with a New Oral Antidepressant. Floden L; Hudgens S; Jamieson C; Popova V; Drevets WC; Cooper K; Singh J CNS Drugs; 2022 Jun; 36(6):649-658. PubMed ID: 35441931 [TBL] [Abstract][Full Text] [Related]
38. Managing dissociative symptoms following the use of esketamine nasal spray: a case report. Pereira S; Brennan E; Patel A; Moran M; Wallier J; Liebowitz MR Int Clin Psychopharmacol; 2021 Jan; 36(1):54-57. PubMed ID: 32804743 [TBL] [Abstract][Full Text] [Related]
39. Appraising esketamine nasal spray for the management of treatment-resistant depression in adults: Number needed to treat, number needed to harm, and likelihood to be helped or harmed. Citrome L; DiBernardo A; Singh J J Affect Disord; 2020 Jun; 271():228-238. PubMed ID: 32479321 [TBL] [Abstract][Full Text] [Related]
40. Comparability of blinded remote and site-based assessments of response to adjunctive esketamine or placebo nasal spray in patients with treatment resistant depression. Targum SD; Daly E; Fedgchin M; Cooper K; Singh JB J Psychiatr Res; 2019 Apr; 111():68-73. PubMed ID: 30685564 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]